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DOI: http://dx.doi.org/10.1016/j.hemonc.2013.02.001BACKGROUND AND OBJECTIVES: Autophagy is a self-degradation mechanism induced under stress condi-
tions in all eukaryotic cells. Its activity in human lymphomas has not been studied as yet.
METHODS: In this study, the autophagic activity of lymphoid cells was investigated in follicular lymphomas
(FL; 48 cases), diffuse large B-cell lymphomas (DLBCL; 78 cases), and in reactive follicular hyperplasias (41
cases), using the light chain 3A (LC3A) antibody and a standard immunohistochemical technique.
RESULTS: In all cases, the pattern of LC3A reactivity was uniformly diffuse cytoplasmic, but expressed more
frequently in FLs (68.8%) than in DLBCLs (41%) (p = 0.02), and much more commonly in DLBCLs than in
reactive lymph nodes (24.3%) (p < 0.006). Interestingly, FLs expressing LC3A in >10% of lymphoid cells (high
reactivity) were associated with the hypoxia-related protein HIF1a and the enzyme of anaerobic metabolism
lactate dehydrogenase LDH5 (p = 0.004 and p = 0.003, respectively). Such associations, however, were not a
feature in DLBCLs of increased LC3A activity.
CONCLUSIONS: LC3A expression in FLs is hypoxia-induced, whereas its expression in DLBCLs may be regu-
lated by other molecular mechanisms. The current study provides a tool for further assessment of autophagic
activity in translational and autophagy targeting therapy studies.Follicular lymphoma (FL) is a relativelycommon B-cell neoplasm (about 22% of thetotal)1 with an indolent clinical course which,
however, is interrupted by frequent relapses.2 It has a
tendency for histological transformation to diffuse
large B-cell lymphoma (DLBCL),3 a much more se-
vere form of the disease. DLBCL remains the most
common type of non-Hodgkin lymphoma, accounting
for 30–40% of all human lymphoid neoplasias.3,4 It is
a rather aggressive, clinically heterogeneous neo-
plasm5–8 and an important cause of disease-speciﬁc
death.2
Autophagy is a self-degradation mechanism by
which cells recycle their own cytoplasmic constituents
to survive suboptimal micro-environmental condi-
tions, such as starvation and oxygen deprivation.9–11
This is accomplished by disposing of excess or defec-Hetive organelles and long-lived proteins into the
lysosomes, forming the so-called autophagic vacuoles.
Although autophagy is a major cell survival pathway,
its excessive activation may lead to massive degrada-
tion of cellular components shifting the balance to self
destruction – the so-called autophagic cell death. The
role of autophagy in the growth and progression of
human malignancies has only recently emerged,
mainly as a marker of aggressive behaviour for epithe-
lial tumours,12–16 but its signiﬁcance in haematologi-
cal/lymphoid neoplasms remains completely obscure.
In this study, we investigated the autophagic activ-
ity in a series of FL, DLBCL, and reactive follicular
hyperplasias, using the light chain 3A (LC3A) anti-
body recognizing both the soluble (LC3A-I) and the
membrane-bound form (LC3A-II) of the protein.17,18
The results were related with intratumoral hypoxia, asmatol Oncol Stem Cell Ther 6(1) First Quarter 2013 hemoncstem.edmgr.com
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assessed by the expression of hypoxia inducible factors
1a and 2a (HIF1a and HIF2a) and their downstream
proteins vascular endothelial growth factor (VEGF)
and lactate dehydrogenase 5 (LDH5).19,20MATERIALS AND METHODS
Tissue microarrays (TMA) prepared from parafﬁn
blocks of hyperplastic and neoplastic lymph nodes were
obtained from patients with follicular lymphomas (FL;
48 cases), diffuse large B-cell lymphomas (DLBCL; 78
cases), and reactive lymph nodes (41 cases). The mate-
rial was collected from the archives of the Department
of Cellular Pathology, John Radcliffe Hospital, Ox-
ford, UK, and ethical approval was obtained from
appropriate Institutional Boards for this study.
The tissues were primarily stained for LC3A to as-
sess autophagic reactivity in lymphoid tissues. The re-
sults were correlated with the hypoxia inducible
factors 1a and 2a (HIF1a, HIF2a), and their down-
stream proteins lactate dehydrogenase 5 (LDH5) and
vascular endothelial growth factor (VEGF). A stan-
dard immunohistochemical technique was used. Ta-
ble 1 shows details of the primary antibodies, the
working dilutions and the antigen retrieval methods
used in this study.12,21–23
Immunohistochemistry for LC3A and other mark-
ers. The primary antibody used was a puriﬁed rabbit
polyclonal antibody (AP1805a, Abgent, San Diego
CA) capable of detecting both the LC3A-I and
LC3A-II forms. The antibody does not recognize
the LC3B form (data not shown). A standard immu-
nohistochemical technique was employed as previ-
ously described.12 In brief, 3 lm thick sections were
de-waxed and rehydrated in graded alcohol solutions.
For heat-induced epitope retrieval, the sections were
placed in citrate buffer (1:10 dilution, pH 7.2) and
heated at 120 C for 3 · 5 min. Endogenous peroxi-
dase activity was neutralized using Peroxidase Block
for 5 min. The non-speciﬁc binding was blocked by
pre-incubation with Protein Block for 5 min at room
temperature (Novocastra Laboratories Ltd., Newcas-
tle upon Tyne, UK). Slides were then incubated over-
night at 4 C with LC3A-II primary antibody diluted
1:20 (Abgent, San Diego, CA). The slides were
washed with PBS (2 · 5 min) and then incubated
with Post Primary Block for 30 min at room temper-
ature (Novocastra Laboratories Ltd., Newcastle upon
Tyne, UK). They were subsequently washed in PBS
for 2 · 5 min and incubated with NovoLink poly-
mer for 30 min at room temperature (Novocastra
Laboratories Ltd., Newcastle upon Tyne, UK). After
a thorough washing in BS (2 · 5 min), the colourHematol Oncol Stem Cell Ther 6(1) First Quarter 2013 hemoncstem.edmgr.comreaction was developed in 3,30-diaminobenzidine
(DBS) for 5 min. The sections were then counter-
stained with hematoxylin, dehydrated and mounted.
Controls
Normal rabbit immunoglobulin-G was substituted for
the primary antibody as negative control. Staining
with omission of the primary antibody was also per-
formed as negative control.
Evaluation of LC3A reactivity, and other
immunohistochemical markers
After immunohistochemical staining for LC3A, nor-
mal and malignant lymphoid cells showing a diffuse
brown reactivity of the cytoplasm were recorded as
positive. Other patterns of LC3A reactivity, such as
a distinct linear condensation of stain around the nu-
cleus (cytoplasmic/perinuclear pattern) or compact,
amorphous, spheroidal structures within cytoplasmic
vacuoles, the so-called ‘‘stone-like’’ structures (SLS),
were not detected in malignant lymphomas or reactive
lymph nodes.
The proportion of lymphoid cells with a diffuse
cytoplasmic staining was determined in all optical ﬁelds
at 200·magniﬁcation, and expressed as the mean of all
counts. The cases under investigation were divided into
groups of low and high LC3A reactivity, as follows.
Tumours with an LC3A staining in more than
10% of neoplastic lymphoid cells were considered as
being of high LC3A reactivity.
The reactivity of HIF1a, HIF2a and LDH5 was
mixed cytoplasmic and nuclear. Lymphoid tumours
with nuclear HIF1a expression in more than 10%
of neoplastic cells and/or a strong cytoplasmic expres-
sion in more than 50% of such cells were considered
to be of high reactivity. The HIF2a and LDH5 reac-
tivity was evaluated in a similar manner.
The reactivity of VEGF was purely cytoplasmic.
The proportion of lymphoid cells with cytoplasmic
staining per case was estimated. The median value
was used as a cut-off point to deﬁne lymphomas of
high and low VEGF reactivity.
The assessment was performed blindly by two
independent observers (A.G. and E.S.).
Normal PBMCs
To assess the expression of LC3A and response to
stress signals on normal peripheral blood mononu-
clear cells (PBMCs) with western blot, blood sam-
ples in EDTA were obtained from three healthy
donors and PBMCs were isolated using standard
procedures. The study was approved by the local
Ethics and Scientiﬁc Committees. PBMCs were cul-21
Table 1. Details of the antibodies, dilutions, and antigen retrieval methods used in this study.
Primary Dilution/incubation Antigen
Specificity Source Reference
Antibody Time* Retrieval
AP1805a 1:20 MW** LC3A Abgent, CA 12
ESEE 122 1:20 (overnight) MW HIF-1a Oxford University 21
EP 190b Neat (overnight) MW HIF-2a Oxford University 21
VG1 1:4 (overnight) MW VEGF Oxford University 22
ab9002 1:200 MW LDH5 Abcam, UK 23
*At room temperature.
**Microwave.
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fetal bovine serum, 2 mM L-glutamine, 1% penicillin,
1% streptomycin, at 37 C, 5% CO2 in air in Petri
dishes. PBMCs were collected after four and 24 h fol-
lowing incubation with 100 nM Baﬁlomycin (an agent
that blocks autophagosome/lysosome fusion) and
with 150 mM of the hypoxia mimetic cobalt chloride
(CoCl2). Cultures were thereafter centrifuged for
30 min at 4000 rpm and stored in a sample buffer
(0.5 M Tris [pH 6.8], 10% sodium dodecyl sul-
fate, 0.05% bromophenol blue, 10% b-mercap-
toethanol, 10% glycerol) at 20 C until
analysis. Total protein concentrations were esti-
mated according to the method of Lowry et al.24
Protein extracts (40 lg) were separated on 12.5%
SDS–PAGE gels and transferred to membranes.
The anti-LC3A AP1805a primary antibody was
added at 1:2000 dilution and incubated over-
night at 4 C, incubated for 2 h at room temper-
ature with appropriate secondary antibody,
rinsed, and developed in TMB (KPL Laborato-
ries, Gaithersburg, MD). A molecular weight
marker and protein extracted from normal hu-
man brain, and a tissue known to have a high
concentration of LC3A, were used to verify the
level where the protein bands appear.Statistical analysis
Statistical analysis was performed using the Graph-
Pad Prism 5.0 package (GraphPad, San Diego CA,
www.graphpad.com). The Fisher’s exact test (two-
tailed) was used for testing relationships between cat-
egorical variables. The unpaired two-tailed t-test or
linear regression analysis was used to compare groups
of continuous variables. A p-value less or equal to 0.05
was taken as signiﬁcant.HeRESULTS
The LC3A expression
All positive lymphoid cells in the series, whether reac-
tive or malignant, showed a diffuse cytoplasmic pat-
tern of LC3A staining (Figure 1). The two other
patterns of LC3A expression, the cytoplasmic/perinu-
clear and the so-called ‘‘stone-like’’ structures (SLS),
previously described in malignant epithelial tu-
mours,12–16 were not observed in malignant lympho-
mas or reactive follicular hyperplasias. In western blot
analysis (Figure 1f) normal PBMCs had very low lev-
els of LC3A expression that were increased, mainly
4 h, after incubation with baﬁlomycin (accumulation
of autophagosomes due to disrupted lysosomal fu-
sion) and with Cocl2 (hypoxia mimetic agent).
LC3A reactivity was high in 33/48 (68.8%) FL,
but only in 32/78 (41%) DLBCLs. This difference
was statistically signiﬁcant (p = 0.02). The
mean ± SD percentage of lymphoid cells with
LC3A expression was 38 ± 32% vs. 24 ± 34%,
respectively (p = 0.02; Figure 2). With regard to the
large cells (centroblasts) in follicular lymphomas,
these expressed LC3A in a similar proportion to that
of the centrocytes.
Cytoplasmic LC3A reactivity in more than 10%
of lymphoid cells was also seen in reactive lymph
nodes, but such an expression was present in
10/41 (24.3%) cases and restricted to the germinal
centers. The mantle zone and the interfollicular
area remained unreactive. It is obvious that both
types of lymphoma had a signiﬁcantly higher
cytoplasmic LC3A reactivity than normal germinal
centers (8 ± 17%) (p < 0.006).
Association of LC3A expression with hypoxia
molecular variables. The association of LC3A
expression with various markers upregulated by hy-matol Oncol Stem Cell Ther 6(1) First Quarter 2013 hemoncstem.edmgr.com
Figure 1. Diffuse cytoplasmic LC3A expression in FL (1a: x20, 1b: x40), DLBCL (1c: x20, 1d: x40) and in a reactive germinal center (1c, x20). Western blot analysis (1f) of normal
PBMCs under various stess: A = molecular weight marker, B = normal brain with high LC3A expression, C and F = PBMCs in culture medium show low levels of LC3A, D and
E = 100 nM of Bafilomycin induce slightly LC3A after 4 h and 24 h incubation respectively, G = PBMCs exposed to 150 lM Cocl2 for 4 h show slight increase of LC3A levels.
Figure 2. Schematic representation of cytoplasmic reactivity of LC3A in
FL, DLBCL, and reactive germinal centers expressed as percentage of
positive lymphocytes.
OVEREXPRESSION OF LC3A AUTOPHAGY PROTEIN IN FOLLICULAR original research reportpoxia and anaerobic metabolism are shown in
Table 2.
FLs expressing high LC3A reactivity were associ-
ated with the hypoxia-related protein HIF1a
(p = 0.004), and the enzyme of anaerobic metabolism
LDH5 (p = 0.003). Such associations were not ob-
served in DLBCLs expressing LC3A in more than
10% of lymphoid cells. No other signiﬁcant associa-
tions were observed.Hematol Oncol Stem Cell Ther 6(1) First Quarter 2013 hemoncstem.edmgr.comDISCUSSION
Autophagy is a common biological process activated
under stress conditions in all eukaryotic cells including
normal and neoplastic lymphocytes.9–11 For, indeed,
normal lymphoid cells exploit the phenomenon of
autophagy to ensure lymphocyte maturation, prolifer-
ation, and survival; the redundant or faulty cellular
constituents (long-lived proteins and dysfunctional
organelles) may be selectively sequestered into auto-
phagosomes and delivered to lysosomes for degrada-
tion and production of energy.25–28 Furthermore,
the neoplastic lymphoid cells may ensure their own
survival by upregulating the same autophagic
machinery.11
In this study, the state of autophagic activity was
evaluated in FL and DLBCL after immunohistochem-
ical staining for the LC3A antibody. In all cases, the
reaction was diffuse cytoplasmic, corresponding pre-
sumably to the soluble form LC3A-I. It was more
common in FL than in DLBCL, but it also occurred
within reactive germinal centers, albeit in scanty lym-
phocytes. These ﬁndings reafﬁrm the upregulated state
of autophagy in neoplastic tissues and reinforced its
role in intra-nodal lymphocyte maturation and/or
proliferation. Other patterns of LC3A expression,
namely the cytoplasmic/perinuclear and the so-called23
Table 2. Association of LC3 expression with hypoxia molecular variables in FL and DLBCL
FL DLBCL
Low High p-value Low High p-value
HIF1a
Low 12 11 0.004 17 9 0.47
High 3 22 29 23
HIF2a
Low 12 19 0.19 32 19 0.46
High 3 14 14 13
VEGF
Low 11 21 0.74 23 14 0.64
High 4 12 23 18
LDH5
Low 10 7 0.003 9 4 0.54
High 5 26 37 28
24
original research report OVEREXPRESSION OF LC3A AUTOPHAGY PROTEIN IN FOLLICULAR‘‘stone-like’’ structures (SLS) which have been de-
scribed previously in malignant epithelial tumors,12–16
were completely absent from lymphoid tissues, both
normal and malignant.
That FLs with an increased cytoplasmic LC3A
expression are related to HIF1a over-expression and
with its downstream protein LDH5 conforms with
the contention that autophagy (as deduced from the
increased expression of LC3A, and from cell cul-
tures)12 is induced by hypoxia. The latter triggers
the release of hypoxia inducible factors 1a and 2a
(HIF1a and HIF2a) which are key transcription fac-
tors regulating the expression of angiogenic factors,
such as the vascular endothelial growth factor
(VEGF), and enzymes, such as lactate dehydrogenase
5 (LDH5), that shift oxygen phosphorylation to
anaerobic glycolysis.19 More recently, it has been
shown that under severe and prolonged hypoxia, an
autophagic response may be facilitated further by
the activating transcription factor 4 (ATF4) which
plays a major role in the regulation of autophagic
machinery, particularly in response to endoplasmic
reticulum (ER) stress.29HeAn analogous association between LC3A and
HIF1a has not been established for DLBCLs, and
it is reasonable to infer that in this particular neo-
plasm, autophagic activity may operate through a
HIF-independent pathway. It has been shown, for
example, that autophagy is speciﬁcally induced by
infection with intracellular pathogens,30 and apoptotic
signaling through B-cell antigen receptor (BCR) stim-
ulation – BCR-mediated autophagy.26 Such apop-
totic stimuli were most commonly found in
neoplastic cells.31
This study provides evidence that increased auto-
phagic activity occurs in both types of lymphomas
under investigation, and with a higher frequency
in FLs than in DLBCLs. FLs expressing LC3A
are closely linked with hypoxia and anaerobic
metabolism whilst DLBCLs are not, indicating an-
other non-hypoxia induced mechanism of autopha-
gic process. As autophagy seems to be a major
mechanism involved in lymphoma response to vari-
ous cytotoxic and targeted agents, a tool is herein
provided for further assessment in translational
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